| Q36989599 | A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone |
| Q35833294 | A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder |
| Q34174609 | A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting |
| Q45996927 | A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. |
| Q34510493 | A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q36853249 | A case series: evaluation of the metabolic safety of aripiprazole |
| Q36843480 | A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice |
| Q44497633 | A comparison of psychotropic medication prescribing patterns in East of England prisons and the general population |
| Q34750070 | A cross-sectional study of the phenotypes of obesity and insulin resistance in adults with down syndrome |
| Q35156543 | A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. |
| Q46890981 | A patient with type B insulin resistance syndrome, responsive to immune therapy |
| Q59789965 | A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia |
| Q36424640 | A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression |
| Q37172973 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) |
| Q47242918 | A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients |
| Q24678461 | A roadmap to key pharmacologic principles in using antipsychotics |
| Q37854834 | A systematic review of metformin to limit weight-gain with atypical antipsychotics |
| Q37531967 | A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole |
| Q49949879 | Access to the CNS: Biomarker Strategies for Dopaminergic Treatments |
| Q36371905 | Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site |
| Q37128933 | Acute and long-term adverse effects of antipsychotics |
| Q35675775 | Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. |
| Q37183591 | Addressing cardiometabolic risk during treatment with antipsychotic medications |
| Q36060420 | Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment |
| Q36136886 | Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial |
| Q97418693 | Advances toward precision medicine for bipolar disorder: mechanisms & molecules |
| Q28553358 | Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study |
| Q36942823 | Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs |
| Q34706471 | Adverse drug reaction monitoring in psychiatry out-patient department of an Indian teaching hospital |
| Q33835333 | Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care |
| Q28660933 | Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease |
| Q37220392 | Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks |
| Q21561008 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain |
| Q46533503 | Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder |
| Q38655964 | An Overview of Links Between Obesity and Mental Health |
| Q37062558 | An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia |
| Q48908840 | An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses |
| Q28543222 | An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine |
| Q36795525 | An outcome measure in schizophrenia: mortality |
| Q35375788 | Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine |
| Q35957173 | Animal models of eating disorders |
| Q34345246 | Anti-psychotic prescription pattern: A preliminary survey of Psychiatrists in India |
| Q43245188 | Antihistaminergic antipsychotics cause weight gain |
| Q47723761 | Antipsychotic activity of standardized Bacopa extract against ketamine-induced experimental psychosis in mice: Evidence for the involvement of dopaminergic, serotonergic, and cholinergic systems |
| Q39889353 | Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes |
| Q37043479 | Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome |
| Q37160453 | Antipsychotic induced weight gain in schizophrenia:mechanisms and management |
| Q38468745 | Antipsychotic medication in schizophrenia: a review |
| Q34194447 | Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization |
| Q36852489 | Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis |
| Q37710090 | Antipsychotics activate the TGFβ pathway effector SMAD3 |
| Q35004010 | Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat |
| Q34661651 | Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients |
| Q38217992 | Antipsychotics use in children and adolescents: An on-going challenge in clinical practice |
| Q38214498 | Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. |
| Q38223569 | Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia |
| Q49608961 | Aripiprazole Lauroxil: A Review in Schizophrenia |
| Q46446352 | Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors |
| Q57612470 | Aripiprazole in Bipolar Disorder |
| Q41529267 | Aripiprazole in the treatment of Huntington's disease: a case series |
| Q35098039 | Aripiprazole maintenance increases smoked cocaine self-administration in humans |
| Q24615556 | Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities |
| Q37373691 | Arterial Stiffness in Patients Taking Second-generation Antipsychotics. |
| Q38070179 | Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults |
| Q49825413 | Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study. |
| Q92136179 | Assessment of lipid response to acute olanzapine administration in healthy adults |
| Q93185385 | Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia |
| Q53234030 | Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. |
| Q43053801 | Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. |
| Q35064650 | Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication |
| Q51371509 | Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy. |
| Q47301630 | Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis |
| Q48124681 | Atherosclerotic Surrogate Markers in Adults With Down Syndrome: A Case-Control Study. |
| Q42497888 | Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis |
| Q38183274 | Atypical antipsychotic-induced metabolic disturbances in the elderly |
| Q34006864 | Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles |
| Q38076320 | Atypical antipsychotics and diabetic ketoacidosis: a review |
| Q33928935 | Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications |
| Q34117015 | Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents |
| Q92626334 | Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review |
| Q37698621 | Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria |
| Q38826206 | BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. |
| Q47925621 | BMI independently relates to glycaemia in patients with severe enduring mental illness (SMI). |
| Q36970128 | Balancing efficacy and safety in treatment with antipsychotics. |
| Q37707188 | Barriers and facilitators of a healthy lifestyle among persons with serious and persistent mental illness: perspectives of community mental health providers |
| Q90084710 | Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice |
| Q36634433 | Bipolar depression: diagnostic and treatment considerations |
| Q34613859 | Blood lactate levels in patients receiving first- or second- generation antipsychotics. |
| Q54942497 | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. |
| Q34641561 | Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis |
| Q36268243 | COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date |
| Q33155805 | Cardiac side effects of psychiatric drugs |
| Q33795131 | Cardiometabolic Health in Bipolar Disorder |
| Q37712697 | Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment |
| Q35087495 | Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study |
| Q37788533 | Cardiovascular aspects of antipsychotics |
| Q36870063 | Cardiovascular effects of antipsychotics |
| Q33440011 | Care for patients with severe mental illness: the general practitioner's role perspective |
| Q36468328 | Challenges associated with controlled psychopharmacological research trials in adolescents with eating disorders. |
| Q39342764 | Challenges encountered in the conduct of Optimal Health: A patient-centered comparative effectiveness study of interventions for adults with serious mental illness |
| Q33632560 | Change in body mass index before and after Alzheimer's disease onset |
| Q31145823 | Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 |
| Q50546113 | Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study. |
| Q37161980 | Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine |
| Q28555023 | Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance |
| Q51185707 | Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. |
| Q38438041 | Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations |
| Q36206591 | Clozapine modifies the differentiation program of human adipocytes inducing browning |
| Q47429942 | Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. |
| Q46098816 | Clozapine-associated weight loss |
| Q50773348 | Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. |
| Q92621898 | Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics |
| Q26773288 | Concerns about quetiapine |
| Q38283039 | Concomitant Use of Topiramate Inducing Neutropenia in a Schizophrenic Male Stabilized on Clozapine |
| Q49885361 | Consequences of Undocumented Medication Use. |
| Q37192896 | Considerations regarding the genetics of obesity |
| Q88581527 | Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes |
| Q41656775 | Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia |
| Q35172283 | Course of health care costs before and after psychiatric inpatient treatment: patient-reported vs. administrative records. |
| Q58780376 | Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders |
| Q28079821 | Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review |
| Q79858778 | Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism? |
| Q49120111 | Development of a health screening clinic |
| Q37613388 | Development of diabetes mellitus associated with quetiapine: A case series. |
| Q36777672 | Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications |
| Q46642105 | Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study |
| Q38826676 | Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review |
| Q36143815 | Diabetes and glucose disturbances in patients with psychosis in Sweden |
| Q34069228 | Diabetes mellitus and suicide |
| Q37163569 | Diabetic control and atypical antipsychotics: a case report |
| Q34459114 | Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments |
| Q92637067 | Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services |
| Q39436079 | Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation |
| Q33707663 | Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? |
| Q37281587 | Does antipsychotic polypharmacy increase the risk for metabolic syndrome? |
| Q36826582 | Dopamine 2 Receptor Genes Are Associated with Raised Blood Glucose in Schizophrenia |
| Q40218754 | Double jeopardy for the mentally ill: higher cardiovascular risk and reduced frequency of certain interventional procedures |
| Q33946973 | Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery |
| Q37681620 | Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria. |
| Q43120982 | Early intervention in psychosis: keeping the body in mind |
| Q21284525 | Eating disorders in schizophrenia: implications for research and management |
| Q36194233 | Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease |
| Q46150855 | Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development |
| Q50987064 | Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats. |
| Q36075717 | Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study |
| Q34661011 | Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis |
| Q33914295 | Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial |
| Q64915990 | Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression. |
| Q36223890 | Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study |
| Q42162953 | Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial |
| Q36241602 | Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia |
| Q36573210 | Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys |
| Q40295381 | Effects of lisdexamfetamine in a rat model of binge-eating |
| Q47302385 | Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats |
| Q35191252 | Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study |
| Q36756154 | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial |
| Q33503890 | Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects |
| Q41733975 | Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients. |
| Q34791688 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study |
| Q35143365 | Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review |
| Q37737291 | Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression |
| Q34124590 | Engaging families in research to determine health literacy needs related to the use of second-generation antipsychotics in children and adolescents |
| Q35844191 | Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. |
| Q27021810 | Epigenetic mechanisms in mood disorders: targeting neuroplasticity |
| Q90731688 | Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting |
| Q37625064 | Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls |
| Q48933903 | Evidence-based pharmacotherapy of schizophrenia |
| Q33663582 | Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors |
| Q50606762 | Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. |
| Q38246512 | Excess mortality in bipolar disorders |
| Q33256430 | Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report |
| Q49456987 | Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice |
| Q33845881 | First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents |
| Q40165139 | First-episode psychosis: a window of opportunity for best practices |
| Q33488312 | Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data |
| Q64039164 | From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone |
| Q24685521 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase |
| Q92713065 | Galphimia glauca and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice |
| Q47332928 | Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters |
| Q37661867 | Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. |
| Q40562486 | Genetic Determinants of Clozapine-Induced Metabolic Side Effects |
| Q37365437 | Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder |
| Q36698123 | Genetic underpinnings of left superior temporal gyrus thickness in patients with schizophrenia |
| Q33257886 | Genetics of antipsychotic treatment emergent weight gain in schizophrenia |
| Q36817242 | Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications. |
| Q40590073 | Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample |
| Q38708352 | Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes |
| Q34631699 | Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. |
| Q37131022 | Guideline-concordant antipsychotic use and mortality in schizophrenia |
| Q47274265 | HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis |
| Q36593819 | Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. |
| Q36375877 | Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment. |
| Q55479566 | High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. |
| Q38430215 | Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience |
| Q37187021 | Homocysteine levels in patients with schizophrenia on clozapine monotherapy |
| Q88938477 | Hospital-Based Quality Measures for Pediatric Mental Health Care |
| Q37535043 | How quickly do physicians adopt new drugs? The case of second-generation antipsychotics |
| Q94561344 | Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics |
| Q37060706 | Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin |
| Q33737076 | Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder |
| Q39167145 | Implementation of a Reverse Colocation Model: Lessons from Two Community Behavioral Health Agencies in Rural Pennsylvania |
| Q43510246 | Implementation of a weight loss program for Latino outpatients with severe mental illness |
| Q53834183 | Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine. |
| Q36510504 | Improving lifestyle interventions for people with serious mental illnesses: Qualitative results from the STRIDE study |
| Q35019136 | Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial |
| Q45893502 | In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic |
| Q48292762 | In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain |
| Q37464232 | Increasing use of atypical antipsychotics and anticonvulsants during pregnancy |
| Q36374128 | Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. |
| Q37095956 | Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. |
| Q36301864 | Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics |
| Q28608153 | Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review |
| Q36111806 | Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior |
| Q53006399 | Interpreting the efficacy findings in the CATIE study: what clinicians should know. |
| Q36377890 | Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review |
| Q51912991 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. |
| Q34785866 | Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial |
| Q36921831 | Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record |
| Q26752771 | Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines |
| Q39158338 | Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics? |
| Q27027832 | Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients |
| Q36729616 | Lack of insight in schizophrenia: impact on treatment adherence |
| Q36113742 | Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study |
| Q37674020 | Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder |
| Q55405731 | Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice. |
| Q47279555 | Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone |
| Q42601640 | Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia |
| Q36433993 | Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis |
| Q85278128 | Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys |
| Q99402127 | Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia |
| Q57181189 | Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy |
| Q36987106 | Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. |
| Q37481134 | Management of Older Inpatients Who Refuse Nonpsychiatric Medication Within Birmingham and Solihull Mental Health NHS Foundation Trust: Audit |
| Q24610124 | Management of antipsychotic-related weight gain |
| Q37423313 | Management of patients presenting with acute psychotic episodes of schizophrenia. |
| Q37631787 | Mania and mortality: why the excess cardiovascular risk in bipolar disorder? |
| Q47753742 | Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats |
| Q50156396 | Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment |
| Q89329532 | Medical mimics: Differential diagnostic considerations for psychiatric symptoms |
| Q37722004 | Medication errors in psychiatry: a comprehensive review |
| Q34691850 | Metabolic Abnormality and Sleep Disturbance are Associated with Clinical Severity of Patients with Schizophrenia |
| Q89091008 | Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial |
| Q37801922 | Metabolic Syndrome in Severe Mental Disorders |
| Q36474147 | Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective |
| Q37947095 | Metabolic and cardiovascular adverse effects associated with antipsychotic drugs |
| Q37900615 | Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials |
| Q37496873 | Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients |
| Q35330607 | Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics |
| Q36703845 | Metabolic drug interactions with newer antipsychotics: a comparative review. |
| Q79829709 | Metabolic findings from the CATIE trial and their relation to tolerability |
| Q26783003 | Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management |
| Q36577861 | Metabolic monitoring for patients treated with antipsychotic medications |
| Q51391762 | Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone |
| Q37189197 | Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes |
| Q88808771 | Metabolic side effects of atypical antipsychotics in older adults |
| Q30459096 | Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. |
| Q37738743 | Metabolic syndrome associated with schizophrenia and atypical antipsychotics |
| Q37129646 | Metabolic syndrome in people with schizophrenia: a review. |
| Q37102229 | Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients |
| Q34037969 | Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study |
| Q47351095 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study |
| Q36156730 | Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis |
| Q39888640 | Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. |
| Q41849512 | Modulation of conditioned avoidance response and quetiapine-induced metabolic syndrome by rosuvastatin and CDP-choline in rats |
| Q30558767 | Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation |
| Q48015522 | Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers |
| Q92001384 | Monitoring the physical health of individuals with serious mental illness |
| Q92168500 | Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program |
| Q35586433 | Multiple risk-behavior profiles of smokers with serious mental illness and motivation for change |
| Q34111775 | Neuroprogressive effects of lifetime illness duration in older adults with bipolar disorder |
| Q38233857 | New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways |
| Q47305725 | No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs |
| Q35074667 | Obesity and coronary risk in patients treated with second-generation antipsychotics |
| Q37416376 | Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects |
| Q64276340 | Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats |
| Q37252495 | Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues |
| Q37809849 | Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia |
| Q43211028 | Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial |
| Q33942644 | Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. |
| Q37494988 | Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up |
| Q36390846 | Olanzapine/fluoxetine combination for bipolar depression |
| Q47242174 | Omega-3 fatty acids supplementation with lithium and aripiprazole for improving the balance of circulating hormones and brain neurotransmitters in manic mice model |
| Q89330644 | Overcoming barriers to monitoring patients taking second-generation antipsychotics |
| Q41541889 | Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells |
| Q43260115 | P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. |
| Q38163397 | Paliperidone extended-release: safety and tolerability from a metabolic profile perspective |
| Q37285348 | Pancreatitis and diabetic ketoacidosis with quetiapine use |
| Q34726953 | Past and Present Progress in the Pharmacologic Treatment of Schizophrenia |
| Q51910566 | Patient subpopulations with elevated cardiovascular risk pose unique treatment challenges. |
| Q34636572 | Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior |
| Q36833921 | Patterns of psychotropic medication use in inpatient and outpatient psychiatric settings in Saudi Arabia |
| Q43042813 | Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder |
| Q38083647 | Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review |
| Q37220366 | Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications |
| Q38217628 | Pharmacogenetics of second-generation antipsychotics |
| Q36577866 | Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications |
| Q33521748 | Pharmacological management in children and adolescents with pervasive developmental disorder |
| Q34985850 | Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice |
| Q34691376 | Pharmacological treatment of ambulatory schizophrenic patients in Belgium |
| Q37732209 | Pharmacologically-induced metabolic acidosis: a review. |
| Q38132160 | Physical complications in early clozapine treatment: a case report and implications for safe monitoring |
| Q37771647 | Physical health in schizophrenia: a challenge for antipsychotic therapy |
| Q37771645 | Physical health management in psychiatric settings |
| Q34623350 | Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. |
| Q35575577 | Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients |
| Q45319384 | Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project |
| Q38047406 | Positioning mental health nursing practice within a positive health paradigm |
| Q30559039 | Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study |
| Q34082230 | Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid Study |
| Q34995934 | Posttraumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population |
| Q36506812 | Practical considerations for carbamazepine use in bipolar disorder |
| Q37206139 | Practical issues with amisulpride in the management of patients with schizophrenia. |
| Q30503523 | Predicting implementation from organizational readiness for change: a study protocol. |
| Q35997710 | Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status |
| Q36303695 | Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients |
| Q37011220 | Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. |
| Q34993531 | Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female Macaque |
| Q36159743 | Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England |
| Q37053637 | Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran |
| Q34944648 | Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study |
| Q37310164 | Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment |
| Q37791558 | Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. |
| Q38374033 | Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial |
| Q40119718 | Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference |
| Q37190577 | Public-academic partnerships: a program to improve the quality of antipsychotic prescribing in a community mental health system |
| Q33159884 | QT interval duration and dispersion in children and adolescents treated with ziprasidone |
| Q33755431 | Quality of care for cardiometabolic disease: associations with mental disorder and rurality |
| Q36870523 | Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. |
| Q26863435 | Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives |
| Q37425737 | Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study |
| Q35886160 | Receipt of monitoring of diabetes mellitus in older adults with comorbid dementia |
| Q51838849 | Recent Swedish clinical practice guidelines for prevention and management of metabolic risk. |
| Q36063735 | Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs |
| Q38154174 | Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics. |
| Q38132163 | Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine |
| Q37727085 | Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients |
| Q41587365 | Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia |
| Q33662898 | Relationship between Serum Bilirubin Levels and Metabolic Syndrome in Patients with Schizophrenia Spectrum Disorders |
| Q60961783 | Relationship between mortality in people with mental disorders and suicide mortality in China during 2000 to 2014: An observational study |
| Q35744928 | Relative Risk of Acute Myocardial Infarction in People with Schizophrenia and Bipolar Disorder: A Population-Based Cohort Study. |
| Q35062881 | Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse |
| Q47121019 | Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report |
| Q92897789 | Reverse Integration Initiatives for Individuals With Serious Mental Illness |
| Q24657398 | Review of olanzapine in the management of bipolar disorders |
| Q38717462 | Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. |
| Q39652199 | Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory |
| Q43145177 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment |
| Q37079013 | Risperidone-induced acromegaly: a case report |
| Q36564507 | Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial |
| Q35001376 | STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications |
| Q33587032 | Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). |
| Q38099224 | Safety and pharmacokinetics of atypical antipsychotics in children and adolescents |
| Q35026487 | Safety and tolerability of antipsychotics: focus on amisulpride |
| Q37202889 | Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. |
| Q36936347 | Schizophrenia endophenotypes as treatment targets |
| Q98564310 | Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms |
| Q34376884 | Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor |
| Q39353717 | Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies |
| Q37598227 | Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice |
| Q24235758 | Second-generation antipsychotics for anxiety disorders |
| Q36523265 | Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? |
| Q37133664 | Secondary effects of antipsychotics: women at greater risk than men. |
| Q35549916 | Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja |
| Q35153031 | Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy |
| Q55082720 | Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. |
| Q33802927 | Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders |
| Q37289300 | Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? |
| Q47173896 | Smoking and weight among patients using clozapine |
| Q51137100 | Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells. |
| Q53813141 | Synthesis of the olanzapine labeled by carbon-14. |
| Q37137008 | Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem |
| Q36399716 | TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME |
| Q89495962 | THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE |
| Q47361916 | Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis |
| Q36336524 | Targeting the fatty acid transport proteins (FATP) to understand the mechanisms linking fatty acid transport to metabolism |
| Q33566124 | The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements |
| Q37790906 | The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review |
| Q36351299 | The Effects of Chlorpromazine on Reproductive System and Function in Female Rats. |
| Q84655745 | The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology |
| Q26748677 | The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review |
| Q37030657 | The antipsychotic story: changes in prescriptions and overdose without better safety. |
| Q34331882 | The diagnosis and treatment of bipolar disorder: decision-making in primary care |
| Q28569990 | The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats |
| Q37719551 | The effect of serious mental illness on the risk of rehospitalization among patients with diabetes. |
| Q33609974 | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study |
| Q64939436 | The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. |
| Q38170310 | The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity |
| Q34197980 | The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats |
| Q38190416 | The interface of physical and mental health. |
| Q36919963 | The mental health clinic: a new model |
| Q36577856 | The metabolic effects of antipsychotic medications |
| Q46622979 | The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis |
| Q37999568 | The metabolic syndrome in schizophrenia: is inflammation a contributing cause? |
| Q36984231 | The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia |
| Q37079080 | The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review |
| Q36908408 | The prevalence and risk factors of stroke in patients with chronic schizophrenia |
| Q33813264 | The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease |
| Q89340368 | The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis |
| Q39888212 | The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination |
| Q35530114 | The treatment of autism with low-dose phenytoin: a case report |
| Q33718231 | The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia |
| Q58861808 | Thermal stability of aripiprazole monohydrate investigated by Raman spectroscopy |
| Q33765864 | Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats |
| Q36092635 | Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles |
| Q35680962 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. |
| Q37030481 | Translation of the diabetes prevention program into a community mental health organization for individuals with severe mental illness: a case study |
| Q34823805 | Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges |
| Q30489980 | Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial |
| Q38334922 | Treatment of clozapine-associated weight gain: a systematic review. |
| Q36687060 | Treatment of psychosis: 30 years of progress. |
| Q58201746 | Understanding antipsychotic-induced weight gain and other metabolic issues |
| Q37896627 | Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? |
| Q89027481 | Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy |
| Q26827756 | Use of atypical antipsychotics in the elderly: a clinical review |
| Q37356486 | Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness |
| Q35049901 | Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes |
| Q30501289 | Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients |
| Q58778213 | Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study |
| Q47141502 | Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness |
| Q33865310 | Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia |
| Q37016538 | Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients |
| Q36646810 | Warfarin-quetiapine interaction causing hemorrhage |
| Q34486175 | Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia |
| Q42682470 | Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records |
| Q38151453 | Weight considerations in psychotropic drug prescribing and switching |
| Q37865505 | Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. |
| Q34033259 | Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians |
| Q38504254 | Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management |
| Q36555343 | Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia |
| Q50139891 | What Works in a Nurse Led Self-Management Program for Patients with Serious Mental Illness (SMI) and Diabetes (DM). |
| Q28083481 | What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? |
| Q37801988 | Where to Position Clozapine: Re-Examining the Evidence |
| Q36553321 | Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. |
| Q34209287 | Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data |
| Q34966022 | Ziprasidone in the treatment of mania in bipolar disorder |
| Q35577365 | Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles |
| Q40116422 | Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats |
| Q79776053 | [Antipsychotic drug-induced changes in metabolism] |
| Q80015079 | [Differences between men and women in side effects of second-generation antipsychotics] |
| Q87945859 | [Frontal brain volume reduction due to antipsychotic drugs?] |
| Q83130945 | [Metabolic disorders under antipsychotic treatment] |
| Q79327220 | [Pharmacotherapy for schizophrenia] |